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Abstract
Background and Aims: Saccharomyces boulardii (Sb) can protect against intestinal injury and tumor formation, but how this
probiotic yeast controls protective mucosal host responses is unclear. Angiogenesis is an integral process of inflammatory
responses in inflammatory bowel diseases (IBD) and required for mucosal remodeling during restitution. The aim of this
study was to determine whether Sb alters VEGFR (vascular endothelial growth factor receptor) signaling, a central regulator
of angiogenesis.
Methods: HUVEC were used to examine the effects of Sb on signaling and on capillary tube formation (using the ECMatrix
TM
system). The effects of Sb on VEGF-mediated angiogenesis were examined in vivo using an adenovirus expressing VEGF-
A(164) in the ears of adult nude mice (NuNu). The effects of Sb on blood vessel volume branching and density in DSS-
induced colitis was quantified using VESsel GENeration (VESGEN) software.
Results: 1) Sb treatment attenuated weight-loss (p,0.01) and histological damage (p,0.01) in DSS colitis. VESGEN analysis
of angiogenesis showed significantly increased blood vessel density and volume in DSS-treated mice compared to control.
Sb treatment significantly reduced the neo-vascularization associated with acute DSS colitis and accelerated mucosal
recovery restoration of the lamina propria capillary network to a normal morphology. 2) Sb inhibited VEGF-induced
angiogenesis in vivo in the mouse ear model. 3) Sb also significantly inhibited angiogenesis in vitro in the capillary tube
assay in a dose-dependent manner (p,0.01). 4) In HUVEC, Sb reduced basal VEGFR-2 phosphorylation, VEGFR-2
phosphorylation in response to VEGF as well as activation of the downstream kinases PLCc and Erk1/2.
Conclusions: Our findings indicate that the probiotic yeast S boulardii can modulate angiogenesis to limit intestinal
inflammation and promote mucosal tissue repair by regulating VEGFR signaling.
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Introduction
Saccharomyces boulardii (Sb), a nonpathogenic probiotic yeast, has
been used for decades to protect against intestinal injury and
inflammation [1]. Animal and in vitro studies indicate that S.
boulardii can protect against severe diarrhea and enterocolitis
induced by a range of bacterial enteric pathogens including
Clostridium difficile, Vibrio cholerae, Salmonella typhimurium, Shigella
flexneri, enterohemorrhagic E. coli and enteropathogenic E. coli [1–
7]. In human studies S. boulardii treatment significantly reduced the
incidence of simple antibiotic-associated diarrhea, recurrent C.
difficile diarrhea, and traveler’s diarrhea [8–13]. More recent
clinical studies indicate that it may also be effective in inflamma-
tory bowel disease (IBD) [14–17]. However, the mechanisms
underlying the protective actions of Sb are not well understood.
Angiogenesis, the formation of new vasculature from an existing
vascular network, is now recognized to play a critical role in
various human disease processes, including carcinogenesis, tumor
growth, and both acute and chronic inflammation [18–20]. There
is considerable evidence in vivo, including clinical observations in
humans, that abnormal angiogenesis is involved in many disease
conditions including rheumatoid arthritis and other inflammatory
disorders, carcinogenesis, psoriasisand ocular degenerative disor-
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increasing clinical and experimental evidence indicates that
angiogenesis also plays a crucial role in IBD [22–28]. Chronically
inflamed intestinal tissues in IBD display significant alterations in
microvascular physiology and function compared with healthy
intestine and with uninvolved IBD intestine [27,29].
Vascular Endothelial Growth Factor (VEGF) and the associated
family of tyrosine kinase VEGF receptors (VEGFRs) are key
proteins modulating angiogenesis [20,30]. VEGFR types 1 and 2
(VEGFR-1 or Flt-1 and VEGFR-2 or KDR/Flk-1) are high-
affinity transmembrane endothelial cell receptors for VEGF [30].
Of the primary receptors, VEGFR-2 is thought to mediate the
majority of tumor angiogenic effects [19,30]. Binding of VEGF to
these receptors leads to intracellular receptor phosphorylation
which activates various intracellular downstream signaling path-
Figure 1. Oral administration of Sb reduced DSS-colitis induced weight loss, histological damage and neo-vascularization in mouse
colon. We used the murine DSS-colitis model to assess the effect of Sb on neo-vascularization in acute colitis. We administered DSS (4% for 5 days) to
mice to induce colitis. 1A) Daily administration of Sb by gavage significantly attenuated weight-loss (N=5, *p,0.05, **p,0.01). Data points
represent mean relative weight 6 standard error. 1B) Histological scores for several parameters of colonic inflammation on Day 5 were evaluated
[control (N=5), DSS alone (N=5), DSS plus Sb (N=5)]. Data points represent mean score 6 standard error,
**,p ,0.01. Representative H/E stained
colonic images are listed. 1C) Confocal fluorescence images of the colonic microvasculature were taken 10 minutes after i.v injection of Alexa 647
WGA. Three dimensional image reconstructions were translated into two dimensional grayscale images and binarized to black-and-white vascular
patterns for analysis using VESGEN software. Representative images are shown. 1D) Quantitative data are presented in Tables 1 and 2. Comparisons
of vascular network and avascular space indices among control, DSS and DSS+ Sb groups. Compared to control mice, the DSS group had significantly
increased numbers of branch points and density of vessel endpoints (p=0.004, p=0.02 respectively). Sb treatment significantly reduced these DSS
effects (p=0.045, p=0.02 respectively). The mean area per AVS (mm
2) in the lamina propria was reduced in the DSS group compared to the control
group (p=0.01). Sb treatment normalized this effect (p=0.02).
doi:10.1371/journal.pone.0064227.g001
Table 1. Vascular network results (mean 6 std dev).
Groups Control DSS DSS+Sb
vessel diameter (m) 16.460.5 17.660.7 17.461.4
fractional vascular
area
0.27260.02 0.40960.07 0.29360.04
branch point
density (m
21)
326632 9816259 452625
end point density
(m
21)
134655 4 8 6101 266641
doi:10.1371/journal.pone.0064227.t001
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formation [18,19,31,32].
We here demonstrate that Sb can regulate angiogenesis both
in vitro and in vivo, by regulating the VEGFR activation and
modulating capillary vessel formation during inflammatory
responses thus promoting intestinal recovery from colitis.
Materials and Methods
Cells and Reagents
Human unbilical vein endothelial cells (HUVEC) were obtained
from Clonetics. Cells were grown on plates coated with 30 mg/ml
vitrogen in EGM-MV BulletKit (5% fetal bovine serum in
endothelial basic medium (EBM) with 12 mg/ml bovine brain
extract, 1 mg/ml hydrocortisone, 1 ml/ml GA-1000, and hEGF).
HUVEC (passages 3 or 4) that are ,80% confluent were used for
most experiments. Cells were serum-starved in 0.1% fetal bovine
serum in EBM for 24 h prior to testing. Antibodies against Erk,
PLCc, VEGFR2 phosphorylated and/or non-phosphorylated
forms, were purchased from Cell Signaling Technology (Beverly,
MA). Preparation of Saccharomyces boulardii culture supernatant
(SbS) was performed as previously described [33,34]. Briefly,
lyophilized Sb (Biocodex Laboratories, France) was cultured in
RPMI 1640 cell culture medium (100 mg/ml) for 24 hours in
37uC. The suspension was then centrifuged at 9000 g for 15
minutes and the supernatant collected. The supernatant was then
passed through a 0.22 mm filter (Fisher Scientific) and then a 10
kDa cutoff filter (Millipore, MA).
Western Blot Analysis
HUVEC were treated with VEGF (R&D Systems) with and
without SbS at different time points. Treated cells were then lysed
in a lysis buffer (62.5 mM Tris-HCl, 10% glycerol, 2% SDS,
0.01% bromphenol blue, and 1% 2-mercaptoethanol). Equal
amounts of cell extract were fractionated by 4% to 20% gradient
SDS-PAGE, and proteins were transferred onto nitrocellulose
membranes (Bio-Rad) at 300 mA for 3 h. Membranes were
blocked in 5% nonfat dried milk in TBST (50 mM Tris, pH 7.5,
0.15 M NaCl, 0.05% Tween 20) and then incubated with
antibodies directed against phosphorylated and non-phosphory-
lated forms of VEGFR2, phopso-Erk1/2 and PLCc. Membranes
were washed with TBST and incubated with horseradish
peroxidase-labeled secondary antibodies for 1 h. The peroxidase
signal was detected by Supersignal chemiluminescent substrate
(Pierce), and the image of the signal was recorded by exposure to
x-ray film (Fujifilm, Tokyo, Japan).
In Vitro Tube Formation Assay
ECMatrix
TM assay kit (Millipore, Inc.) was used to study the
effects of SbS on HUVEC capillary tube formation in accordance
with the manufacturer’s instructions. HUVEC (,1610
4 cells)
were plated in 96-well plates previously coated with Matrigel and
incubated in triplicates for 16 hours at 37uC in the absence or
presence of SbS at different dilutions. Representative photomi-
crographs of tubule formation from 10 random fields from each
group were captured. Tubular structures were then counted and
expressed as the mean number of tubules expressed as a
percentage of that counted in the control group.
Mouse Ear Vasculature Assay
All animal protocols were approved by the BIDMC IACUC.
Six-week-old, female, athymic, Nu/Nu mice (NCI, Bethesda, MD)
were used in the mouse ear vasculature model as previously
described.[35] A non-replicating adenoviral vector (Ad-VEGF-
A164) engineered to express the predominant (164 aa) murine
isoform of VEGF-A was a generous gift from Dr. Harold Dvorak.
5610
6 pfu of Ad-VEGF-A164 (in 10 mL) were injected into the
dorsal skin of both ears using a 30-gauge needle. The first SbS (or
vehicle) injection was administered s.c. locally (to the ear) 1 hour
after the adenovirus injection. A second SbS (or vehicle) injection
was administered 24 hours later. Ears were photographed on day
16.
Angiogenesis Analysis in DSS-Colitis Model
DSS (4% for 5 days) was administered to 8-week-old female
C57BL6 mice (Jackson Laboratory). Sb was given to mice daily by
oral gavage at a dose of 6610
8 CFU. At Day 5, mice blood vessels
were stained with 50 mg Alexa FluorH 647 WGA (Molecular
Probes) injected retro-orbitally. Seven minutes later, mice were
sacrificed by CO2 asphyxiation. Colon tissues were immediately
removed and rinsed with PBS. Tissue specimens were imaged with
a Bio-Rad Radiance 2000 confocal microscope (Bio-Rad, Hercu-
les, CA). Image acquisitions were carried out with Laser Sharp
Scanning Software (Bio-Rad). Three dimensional analyses were
used to assess the blood vessel volume and density in the mice
colon. Three dimensional image reconstructions were translated
into two dimensional grayscale images and binarized to black-and-
white vascular patterns as described previously [36,37]. The image
of a binary vascular pattern was input into VESsel GENeration
(VESGEN) software and upon selection of the Vascular Network
analysis option. VESGEN automatically mapped and quantified
the vascular pattern. The mapping of networks by VESGEN
excludes any avascular spaces (AVS) located at the edge of the
image because representation of the AVS is incomplete in those
regions and therefore the vascular density is unknown.
Histological Score Assessment of Colitis
H&E-stained colonic sections were coded for blind microscopic
assessment of inflammation for DSS-induced colitis. Histological
scoring includes parameters of colonic inflammation (ulceration,
congestion, edema, and neutrophil infiltration) as previously
reported [38].
Table 2. Avascular spaces (AVS) results (mean 6 std dev).
Groups Control DSS DSS+Sb
number of AVS 100614 240679 10468
mean area (mm
2) per AVS 969261747 321461169 67176480
avascular area fraction (reciprocal of vascular area fraction, Table 1) 0.72860.02 0.59160.07 0.70760.04
doi:10.1371/journal.pone.0064227.t002
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Results were expressed as mean 6 SE or mean 6 STDEV.
Data were analyzed using the SIGMA-STAT
TM professional
statistics software program (Jandel Scientific Software, San Rafael,
CA). Analyses of variance with protected t test were used for
intergroup comparison.
Results
Oral Intake of Sb Inhibits Angiogenesis during DSS
Induced Colitis
Dextran sulfate sodium (DSS) leads to reversible colitis with
pathological angiogenesis in mice [22,23,28]. We therefore used
this colitis mouse model to assess the effect of Sb on the
remodeling of the colonic capillary vasculature during the
induction of colitis. The luminal microvasculature of the normal
intestine is organized as a highly regular ‘honeycomb’ lattice or
network comprised of small diameter, capillary-like vessels
(Figure 1C) surrounding the colon crypts. Three fundamental
characteristics of such vascular networks are: (1) the vascular
fractional area (or volume), (2) regularity of the geometry of the
AVS as defined by network morphology or architecture and (3) a
related characteristic, connectedness of the vascular network. The
vascular fractional area is determined by vessel length and
diameter in comparison to the fractional area of the avascular
spaces (AVS’s). The relationship between the vascular and
avascular fractional areas is inverse and the two fractional areas
must sum to 1.0.
We administered DSS (4% for 5 days) to mice to induce colitis.
As shown in Figure 1A, daily administration of Sb significantly
attenuated weight-loss (N=5, p,0.01) and reduced histological
Figure 2. Sb inhibits VEGF-induced angiogenesis in the mouse
ear vasculature model. The effects of Sb on VEGF-induced
angiogenesis in vivo was assessed using an adenovirus expressing
VEGF-A(164) (Ad-VEGF-A(164)) in the ears of adult nude mice (NuNu).
Ad-VEGF-A164 (5610
6 pfu) was injected into both ears. One hour later
the right ears of mice (N=5) were injected s.c. with 10 ml SbS (ion-
exchange chromatography enriched and DMEM diluted) and the left
ears were injected s.c. with 10 ml vehicle (DMEM) as control. A second
injection of SbS or vehicle was administered 24 hours later. Each of the
5 mice showed an angiogenesis response to Ad-VEGF-A164 in the
control (left) ear. The inhibitory effect of SbS was evident with reduced
new vessel formation in the right ear compared to the left. The images
shown were obtained on day 16 after Ad-VEGF-A164 administration.
doi:10.1371/journal.pone.0064227.g002
Figure 3. Sb inhibits HUVEC capillary tube formation. The
ECMatrix
TM in vitro angiogenesis assay was used to examine the effects
of Sb on capillary tube formation. HUVEC (,1610
4 cells) were cultured
in 96-well plates previously coated with Matrigel and incubated for 16
hours at 37uC in the absence or presence of different doses of SbS.
Representative images of tubule formation in the control and SbS-
treated groups are shown in the lower panel. Tubular structures were
counted from 10 randomly selected images. Percentage (%) of control is
the mean number of tubules expressed as a proportion of that in the
control group. SbS significantly inhibited HUVEC tubule formation in a
dose-dependent manner (*p,0.05 for 1/32 dilution vs control;
**p,0.01 for 1/16, 1/8, 1/4 vs control). Bars represent mean 6 SE.
doi:10.1371/journal.pone.0064227.g003
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tration (Figure 1B). Blood vessels were stained with Alexa FluorH
647 WGA. Colonic tissue specimens were imaged and 3D
reconstructions were completed.
The VESGEN network option analyzed the entire vascular
pattern for vessel parameters (Figure 1C and Table 1), and the
region containing complete AVS for network parameters
(Figure 1C and Table 2). As shown in Figure 1C, the normal
intestinal capillary network displays a highly regular lattice
structure (left column) that was disrupted during severe inflam-
mation caused by DSS and replaced by enhanced angiogenesis
resulting in a vascular network characterized by increased
numbers of branch and end points (right column and Tables 1
and 2). Sb treatment significantly reduced the number of capillary
branch and endpoints indicating a reduced angiogenesis. Sb
treatment also normalized vessel diameter and density in the colon
lamina propria (middle column and Tables 1 and 2). Furthermore,
the mean area per AVS (mm
2) in the lamina propria was
significantly reduced in the DSS group compared to control group
(p=0.01), whereas Sb again normalized the DSS effect (p=0.01)
(Figure 1D).
The reduction of angiogenesis in Sb-treated mice correlated
with significant protection of the treated mice from DSS induced
colitis as indicated by their weight loss and histological scores
compared to control mice (Figure 1A and 1B). Together these data
indicated that Sb could have a novel function in the regulation of
angiogenesis during inflammatory responses leading to reduced
tissue damage and allowing for faster mucosal recovery.
Sb Inhibits VEGF-induced Angiogenesis in a Mouse Ear
Neo-vascularization Model
To determine whether Sb could directly regulate the function of
VEGF, we then went on to assess the effects of Sb on VEGF-
induced angiogenesis in vivo using an adenovirus expressing
VEGF-A(164) (Ad-VEGF-A(164)) in the ears of adult nude mice
(NuNu), an in vivo angiogenesis model as previously reported [35].
The right ears of mice (N=5) were injected with 10 ml SbS (ion-
exchange chromatography enriched and DMEM diluted) and the
left ears were injected with 10 ml vehicle (DMEM) as control. The
first treatment was administered 1 hour after 5610
6 pfu Ad-
VEGF-A(164) was injected into both ears. The second SbS or
vehicle injections were administered 24 hours later. As shown in
Figure 2, each of the 5 mice showed an angiogenesis response to
Ad-VEGF-A(164) in the control (left) ear. By day 7 an inhibitory
effect of SbS was clearly evident with reduced new vessel
formation in the right ear compared to the left. The effect of
SbS remained evident until the end of the experiment on day 21.
These results indicated that SbS mediated inhibition of vessel
formation is mediated by a direct inhibition of VEGF mediated
angiogenesis in vivo.
S. boulardii Inhibits HUVEC Capillary Tube Formation
Endothelial cell capillary tube formation is a multi-step process
involving cell adhesion, migration, differentiation and growth.[21]
We used the ECMatrixTM in vitro angiogenesis assay to study the
effects of SbS on angiogenesis in vitro. HUVEC (,1610
4 cells)
were cultured as triplicates in 96-well plates previously coated with
Matrigel and incubated for 16 hours at 37uC in the absence or
presence of SbS. Representative photomicrographs of tubule
formation in the control and SbS-treated groups are shown in the
lower panel of Figure 3. Tubular structures were then counted.
Percentage (%) of control is the mean number of tubules expressed
as a proportion of that in the control group. As shown in Figure 3,
SbS significantly inhibited HUVEC tubule formation in a dose-
dependent manner (P,0.05 for 1/32 dilution vs control; P,0.01
for 1/16, 1/8 and 1/4 vs control) indicating that, in addition to its
effects on VEGFR signaling, SbS can attenuate angiogenic
responses in vitro.
S. boulardii Inhibits VEGFR Signaling in HUVEC
VEGFRs belong to the same receptor tyrosine superfamily, as
EGFR, IGF-1R, HER-2 and HER-3 which we have demonstrated
to be a target of SbS in colonic epithelial cells [34]. We therefore
examined the activation of VEGFR-2, the most defined and major
mediator of angiogenesis, in HUVEC. Near-confluent (80%
confluent) HUVEC grown in complete medium were exposed to
SbS for varying time periods (0–180 minutes). Cell extracts were
prepared for Western blotting using antibodies against total and
phospho-specific VEGFR-2. As shown in Figure 4A, phosphory-
lated VEGFR-2 was evident under basal conditions and at 60 and
180 minutes of incubation. Phosphorylated VEGFR-2 disap-
peared immediately (within 1 minute) after exposure to SbS. In
contrast, the amount of total VEGFR2 remained stable.
To test whether SbS inhibits ligand-induced VEGFR signaling,
HUVEC (starved overnight) were treated with 10 ng/ml VEGF in
the presence or absence of SbS for 0 to 30 minutes. Cell extracts
were prepared for Western blotting with antibodies against total or
phopho-specific VEGFR-2, PLCc, or Erk1/2. As demonstrated in
Figure 4B, VEGF induced activation of VEGFR-2 phosphoryla-
Figure 4. Sb inhibits VEGFR signaling in HUVEC. 4A) HUVEC
grown normally in complete medium were exposed to SbS for varying
time periods (0–180 minutes). Cell extracts were prepared for Western
blotting using antibodies against total and phopho-specific VEGFR-2.
The band of phosphorylated VEGFR-2 immediately disappeared (within
1 minute) upon exposure to SbS. In contrast, the amount of total
VEGFR2 remained stable. 4B) HUVEC were starved overnight and then
treated with 10 ng/ml VEGF in the presence or absence of SbS for 0 to
30 minutes. Cell extracts were prepared for Western blotting with
antibodies against total or phopho-specific VEGFR-2, PLCc, or Erk1/2.
VEGF induced activation of both VEGFR-2 phosphorylation sites as
recognized by p-Tyr1175 and p-Tyr996 phospho-site specific antibodies.
The downstream mediators PLCc and Erk1/2 are also activated by VEGF.
The presence of SbS inhibited the phosphorylation of VEGFR-2 in
response to VEGF and also reduced activation of the downstream
kinases PLCc and Erk1/2. Total protein levels were not affected.
doi:10.1371/journal.pone.0064227.g004
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minutes. The downstream mediators, PLCc and Erk1/2 were also
activated by VEGF as expected. SbS reduced VEGFR-2
phosphorylation in response to VEGF and also reduced activation
of the downstream kinases PLCc and Erk1/2. Total protein levels
were not substantially altered. Together, these results demonstrate
that SbS has the ability to inhibit VEGFR 2 signaling by
preventing tyrosine phosphorylation required for the activation of
PLCc and Erk1/2 responsible for the proliferation of endothelial
cells during vessel formation.
Discussion
In this study, we propose a new mechanism by which S. boulardii
regulates angiogenesis and controls mucosal inflammation. We
demonstrate that Sb can inhibit VEGFR signaling and capillary
tube formation in HUVEC. Sb can inhibit angiogenesis in vivo
induced either directly by VEGF or by mucosal inflammation after
epithelial barrier disruption by DSS.
For the first time, we were able to quantify vascular network
structure and architecture in control and diseased intestines using
several key parameters including vascular fractional area,
fractional area of avascular spaces, and regularity of the geometry
of avascular spaces, network morphology and the connectedness of
the vascular network. Mapping and quantification by VESGEN
showed that the uniform, lattice-like vascular network evident in
control colonic tissues was greatly disrupted during DSS colitis.
Inflammation greatly increased vessel density and disrupted the
regular lattice geometry of the lamina propria microvasculature.
We were also able to demonstrate that S boulardii treatment
substantially enhanced mucosal recovery and restored the vascular
network to a significant more normal morphology.
There is increasing evidence from experimental mouse models
and from clinical observations that angiogenesis is an important
component of IBD pathogenesis.[24,29] For example, VEGF has
been shown to be elevated in distal colonic tissue in the
CD4+CD45RBhigh colitis model [22] as well as in intestinal
tissues and sera of patients with Crohn’s disease and ulcerative
colitis [39–41]. Recent studies in experimental colitis suggest that
VEGF is an important mediator of IBD through promoting
intestinal angiogenesis and inflammation [28]. Over-expression of
VEGF in mice with DSS-induced colitis worsened their condition,
whereas over-expression of soluble VEGFR, to block VEGF
effects, had a beneficial effect [28]. Therefore, agents that inhibit
VEGF/VEGFR signaling might prove to be useful to reduce
intestinal inflammation in patients with IBD [24,25].
Our work presented here is the first example of a probiotic
possessing anti-angiogenic functions. However, Bacillus polyfermen-
ticus, a prokaryotic probiotic strain, was reported topromote
angiogenesis in the mucosa during recovery of mice from colitis
[42]. Thus, considering probiotics as a single entity is likely to
over-simplify their diverse and complex interactions with the
intestine and its microbiota. On the other hand, angiogenesis may
play different roles during the acute/injury and the recovery/
healing stages of colitis.
S. boulardii appears to exert its therapeutic effect by multiple
mechanisms and to influence several important facets of intestinal
host-pathogen interaction, including neutralization of bacterial
virulence factors [3,43], enhancement of the mucosal immune
response [44–46], interference with bacterial adhesion [3],
strengthening of enterocyte tight junctions [6], altering immune
cell redistribution [47] and modulating inflammatory signaling
pathways of the host [33,34,48]. It will need to be established,
whether the inhibition of vessel formation will result in a reduced
recruitment of inflammatory macrophages, neutrophils or T cells,
thus preventing severe mucosal tissue damage. The anti-angio-
genesis property demonstrated in this study adds another novel
mechanism of action for Sb and perhaps other probiotics.
In this study we report the exciting observation that probiotic
yeast S. boulardii blocks VEGFR signaling and inhibits angiogenesis
both in vitro and in vivo. Furthermore, this study demonstrates the
enormous potential for probiotics to open new avenues toward
understanding the pathogenesis of IBD as well as uncovering novel
options for disease prevention and therapy.
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